Introduction of MMF in conjunction with stepwise reduction of calcineurin inhibitor in stable liver transplant patients with renal dysfunction

Mycophenolat mofetil (MMF) is a new imunosuppressant without nephrotoxic adverse effects. The aim of this study was to evaluate feasibility and effect of MMF introduction in conjunction with stepwise reduction of calcineurin inhibitors (CNI) in stable liver transplant patients with chronic CNI-induc...

Full description

Saved in:
Bibliographic Details
Published in:International immunopharmacology 2005, Vol.5 (1), p.141-146
Main Authors: Kornberg, Arno, Küpper, Bernadette, Hommann, Merten, Scheele, Johannes
Format: Article
Language:English
Subjects:
Adult
Aged
Biological and medical sciences
Blood Pressure - drug effects
Calcineurin inhibitor
Calcineurin Inhibitors
Cardiovascular Diseases - prevention & control
Cholesterol - blood
Creatinine - blood
Female
Humans
Immunomodulators
Immunosuppressive Agents - adverse effects
Immunosuppressive Agents - therapeutic use
Kidney Diseases - etiology
Kidney Diseases - therapy
Liver Transplantation
Male
Medical sciences
Middle Aged
Mycophenolat mofetil
Mycophenolic Acid - adverse effects
Mycophenolic Acid - analogs & derivatives
Mycophenolic Acid - therapeutic use
Pharmacology. Drug treatments
Renal dysfunction
Risk Factors
Urea - blood
Uric Acid - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mycophenolat mofetil (MMF) is a new imunosuppressant without nephrotoxic adverse effects. The aim of this study was to evaluate feasibility and effect of MMF introduction in conjunction with stepwise reduction of calcineurin inhibitors (CNI) in stable liver transplant patients with chronic CNI-induced renal dysfunction (RDF). In the MMF-group ( n=27) but not in the controls ( n=16), mean serum level of creatinine fell from a baseline of 227.4±67.9 μmol/l to 159.2±48.2 μmol/l ( P
ISSN:1567-5769
1878-1705
DOI:10.1016/j.intimp.2004.09.018